Abstract: The present invention provides, inter alia, methods for ameliorating an adverse effect in a patient caused by an acute transfusion into the patient of a composition containing aged red blood cells using an iron chelator. Apparatuses and kits for ameliorating such adverse effects are also provided.
Type:
Application
Filed:
December 1, 2011
Publication date:
November 22, 2012
Inventors:
Steven L. Spitalnik, Eldad A. Hod, Gary M. Brittenham
Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
Type:
Application
Filed:
July 13, 2012
Publication date:
November 1, 2012
Applicants:
INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA, CENIX BIOSCIENCE GMBH
Inventors:
MICHAEL HANNUS, CECILIE MARTIN, MARIA M. MOTA, MIGUEL PRUDENCIO, CHRISTINA DIAS RODRIGUES
Abstract: The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).
Type:
Application
Filed:
December 11, 2009
Publication date:
December 15, 2011
Applicant:
THE UNIVERSITY OF MELBOURNE
Inventors:
Paul Stephen Donnelly, Brett Michael Paterson
Abstract: Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
Type:
Grant
Filed:
January 11, 2007
Date of Patent:
February 22, 2011
Assignee:
President and Fellows of Harvard College
Abstract: Disclosed is a medicament comprising N-aryl N? morpholino/piperidino thiocarbamide derivatives represented by the following formula 1 for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome, and can be used in drugs, foods, and beverages inducing an effect of preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome of modern people who suffer from the increasing development of diabetes resulting from environmental factors, such as intake of westernized foods, obesity, and so on: wherein, X is O or C, and R represents 4-chlorophenyl, 2-methylphenyl, 3-methoxypheny, 3-methylphenyl, or phenyl group.
Abstract: The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.
Type:
Grant
Filed:
December 29, 2003
Date of Patent:
April 21, 2009
Assignee:
Novartis Vaccines & Diagnostics, Inc.
Inventors:
Paul A. Barsanti, Nathan Brammeier, Anthony Diebes, Liana Marie Lagniton, Simon Ng, Zhi-Jie Ni, Keith B. Pfister, Casey Philbin, Nicholas Valiante, Allan S. Wagman, Weibo Wang, Amy J. Weiner
Abstract: An antimicrobial composition suitable for cleaning inanimate surfaces and human skin comprises two or more cationic biocides and two or more biocides which are slower acting than the cationic biocides, wherein each cationic biocide is independently either: (i) a quaternary ammonium compound at a concentration of at least 0.1% w/v; or (ii) a biguanide compound.
Type:
Application
Filed:
March 20, 2006
Publication date:
February 12, 2009
Inventors:
Adrian Fellows, Guy Braverman, Allen Hanouka
Abstract: The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds.
Type:
Grant
Filed:
April 18, 2002
Date of Patent:
June 28, 2005
Assignees:
Vion Pharmaceuticals, Inc., Yale University
Inventors:
Ivan C. King, Terrance W. Doyle, Mario Sznol, Alan C. Sartorelli, Yung-Chi Cheng
Abstract: The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.
Type:
Grant
Filed:
May 8, 2003
Date of Patent:
May 24, 2005
Assignee:
The Regents of the University of California
Inventors:
Fred E. Cohen, Xiaohui Du, Chun Guo, James H. McKerrow
Abstract: The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.
Type:
Application
Filed:
May 8, 2003
Publication date:
January 22, 2004
Applicant:
The Regents of the University of California
Inventors:
Fred E. Cohen, Xiaohui Du, Chun Guo, James H. McKerrow
Abstract: The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.
Type:
Grant
Filed:
October 15, 2001
Date of Patent:
September 16, 2003
Assignee:
Pfizer Inc.
Inventors:
Wesley W. Day, Andrew G. Lee, David D. Thompson
Abstract: Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the “good” cholesterol and as such may be useful for treating diseases such as atherosclerosis.
Abstract: The present invention is directed to optionally substituted 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs thereof, represented by the Formulae I and II: 1
Type:
Application
Filed:
June 3, 2002
Publication date:
March 6, 2003
Inventors:
Sui Xiong Cai, Bao Ngoc Nguyen, John Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Azra Pervin
Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.
Abstract: A method of preparing a radiopharmaceutical in a form suitable for intravenous bolus injection is disclosed. The method comprises eluting .sup.62 Cu from from an anion exchange column loaded with .sup.62 Zn.
Abstract: Therapeutic compounds having the formula: ##STR1## in which R.sub.2 and R.sub.3 independently denote H, C.sub.1 -C.sub.4 alkoxy or OH and (A, B)=(oxygen, oxygen) in which case one out of R and R.sub.1 denotes OH, halogen, secondary amino or tertiary amine and the other denotes NHNHCONHR.sub.4 or R and R.sub.1 together denote .dbd.N--NH--CX--NHR.sub.5, .dbd.N--NH--CX--N(phenyl).sub.2, .dbd.N--NH--CX--NH--NH--R.sub.5, .dbd.N--NH--C(SCH.sub.3).dbd.N--R.sub.6 or .dbd.N--N.dbd.C(SCH.sub.3)--NH--R.sub.6 ; or (A, B)=(N--OH, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2 ; or (A, B)=(N--NH--CX--NHR.sub.5, oxygen) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 ; or (A, B)=(N--OH, N--OH) in which case R and R.sub.1 together form .dbd.N--NH--CX--NHR.sub.5 or .dbd.N--NH--CX--N(phenyl).sub.2.
Type:
Grant
Filed:
March 24, 1994
Date of Patent:
November 5, 1996
Assignee:
Innothera
Inventors:
Michel P. Cugnon de Sevricourt, Catherine G. Dacquet, Michel A. Finet, Florence J. Le Marquer, Max F. Robba, Norbert O. Tembo, Sylvie J. Yannic-Arnoult, Jean-Luc Torregrosa
Abstract: Compounds of formula I ##STR1## wherein A, X, Z and R.sub.1 -R.sub.5 are as defined in the description, and their salts have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.
Type:
Grant
Filed:
November 30, 1994
Date of Patent:
October 24, 1995
Inventors:
Jaroslav Stanek, Jorg Frei, Giorgio Caravatti
Abstract: Compounds of formula I ##STR1## wherein A, X, Z and R.sub.1 -R.sub.5 are as defined in the description, and their salts have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.
Type:
Grant
Filed:
March 28, 1994
Date of Patent:
March 7, 1995
Assignee:
Ciba-Geigy Corporation
Inventors:
Jaroslav Stanek, Jorg Frei, Giorgio Caravatti
Abstract: This invention is directed to heterocyclic and aromatic thiosemicarbazones seful in the treatment of filariasis and in an animal, including humans.
Type:
Grant
Filed:
November 8, 1991
Date of Patent:
January 25, 1994
Assignee:
The United States of America as represented by the Secretary of the Army
Inventors:
John W. McCall, Daniel L. Klayman, Ai Jeng Lin, Kenneth E. Kinnamon, Max Grogl
Abstract: Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a lower aliphatic ester of a lower aliphatic carboxylic acid such as ethyl acetate and a lower alkanol such as propylene glycol. Methods and transdermal drug delivery systems for using the compositions are also provided.
Type:
Grant
Filed:
April 2, 1992
Date of Patent:
August 24, 1993
Assignee:
SRI International
Inventors:
Paul G. Catz, David R. Friend, Harold W. Nolen, III
Abstract: Pharmaceutical combination preparations containing rifampicin and thioacetazon and optionally isonicotinic acid hydrazide or ethambutol and the use of same for the treatment of mycobacterial infections.
Abstract: Certain organic compounds derived from urea or thiourea having insectical activity and methods of their preparation are disclosed. The compounds according to the invention have been found to interfere with the mechanism of metamorphoses which occurs in insects. Hence the substances according to the invention are specifically active against insects. Owing to this specificity and because of the absence of phytotoxicity effects, the compounds of this invention are of prime importance.